TRINAMIC
7.11.2016 16:32:35 CET | Business Wire | Press release
Trinamic Motion Control GmbH & Co. KG, a leading supplier of semiconductors, electronics and mechatronic solutions in the fields of motor and motion control, is proud to announce the arrival of a new family of high-performance semiconductor components for stepper motor control. The TMC2208-LA and TMC2224-LA are monolithic components with integrated circuit breakers for up to 1.2A RMS, and optimal power controllers for noiseless, sinusoidal control of the motor phases. Above all, both components were designed with the goal of easy application in mind. Trinamic will present the drives to the public at Electronica 2016, in Hall A4 at booth 513.
"Developers are under increasing pressure to shorten development cycles and bring new products on the market faster," explains Michael Randt, founder and CEO of Trinamic. "Our new family of drivers has been specially developed to help make the development process as short and as simple as possible."
Enhanced by the flexible microPlyer interpolater unit, the components offer a resolution of up to 256 microsteps-per-full-step to achieve perfect sinusoidal control - even with low-resolution motion controllers. Further development of Trinamic's stealthChop technology, which was introduced two years ago, has all but eliminated motor noise at low speeds, making the precise control of stepper motors not only possible, but affordable for application in environments that demand absolute silence, e.g. office buildings and residential areas.
Due to the immense popularity of stealthChop technology, the components have been designed for compatibility with existing 3D printer electronics. With stealthChop there is no need for costly redesign.
Both components feature a step/direction source for fully autonomous operation. Configuration is achieved via digital inputs.
The components will be available at a price of USD 1.22 at quantities of 1000 as a QFN28 (5x5) package in the first quarter of 2017. To accelerate the design process, Trinamic offers complete end-to-end evaluation kits. The development boards are open-source hardware and freely available for use as a reference design.
About Trinamic
Trinamic, headquartered in Hamburg, provides integrated circuits and motor control modules to customers worldwide. The company's application-driven approach and in-depth understanding of their customers' needs allow them to offer solutions which simplify and shorten the design phase, resulting in significant cost savings, decreased resource allocation and a reduced total cost of ownership. Trinamic's customers benefit from the company's rich expertise in motor physics and extensive portfolio of intellectual property (IP) acquired through many years of applied experience and success. Product development at Trinamic focuses entirely on miniaturizing form factor, increasing efficiency and maximizing the safety and reliability of their products and, thereby, the systems in which they're used.
The company is fully committed to providing energy efficient solutions. Industry-leading technologies such as Trinamic's patented coolStep™ products offer user-friendliness, precise stepper motor control and, above all, energy savings.
The Trinamic Motion Control Language (TMCL) facilitates the development of motor control applications, enabling shorter development cycles and rapid product release.
Over 20 years of experience and a traditional German ownership structure with private shareholders ensure the long-term availability of their products and components.
From the headquarters in Hamburg, Germany, Trinamic products are sold via a worldwide distribution network.
Printable graphics and an English-language version of this press release are available at:
http://www.trinamic.com/company/press/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005244/en/
Contact:
Trinamic
Jonas P. Proeger, +49 (0) 40 514 806-0
Marketing
Director
proeger@trinamic.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom